Back to Trial

Oracle Runs

Oracle findings and outcome history for Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE (NCT05226780).

Runs
4
Findings
4
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public readout available for this Phase 2 extension trial (NCT05226780, est. completion Mar 2026). Trial active not recruiting per sources; primary endpoint safety over 168 weeks not yet reported. Parent study (NCT04873869, Kayak) closed due to insufficient efficacy, but distinct from this safety-focused extension.

Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
ClinicalTrialsclinicaltrials.gov
ClinicalTrials.gov: Extension Study NCT05226780
Active not recruiting; estimated primary completion 2026-03-01. No results posted.
Web Searchthecutesyndrome.com
SCN8A Clinical Trials - The Cure SCN8A Syndrome
Neurocrine Biosciences: NBI-921352 Kayak Study (Discontinued).
Web Searchscn8aalliance.org
Clinical Trials & Emerging Treatments - SCN8A Alliance
Neurocrine has closed the recent Kayak Study (352) ... not sufficient efficacy to continue the trial.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govJul 17, 2025, 12:00 AM
Study Details | NCT05226780 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-03; hasResults=false on the latest posted update.
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy/safety readout was found for NCT05226780. ClinicalTrials.gov still describes it as an extension study, while Neurocrine’s 2025 letter says NBI-921352 development in SCN8A-DEE was discontinued but the ongoing DEE2013 extension remains open. That is program-level negative context, not a clear readout for this exact trial.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05226780 | Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
ClinicalTrials.gov lists NCT05226780 as the extension study for NBI-921352 in SCN8A-DEE; the page snippet describes the study but does not provide a posted positive or negative readout.
Sponsorscn8aalliance.orgFeb 1, 2025, 12:00 AM
Dear SCN8A Patient Community
Neurocrine says it will discontinue NBI-921352 development for SCN8A-DEE because the data did not fulfill all qualities of a beneficial treatment, but also says the ongoing clinical study DEE2013 will remain open for existing participants.
NO_DECISIONDismissed89% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear trial-specific efficacy/safety readout was found for this extension study. ClinicalTrials.gov still shows NCT05226780 as ongoing/active with estimated completion in March 2026, and a 2025 Neurocrine letter discusses discontinuing NBI-921352 broadly while keeping DEE2013 open, which is program-level and not a clear positive/negative readout for this exact trial.

Found Apr 1, 2026, 7:50 PMReviewed Apr 1, 2026, 8:21 PM
ClinicalTrialsclinicaltrials.govJul 17, 2025, 12:00 AM
Study Details | NCT05226780 | Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
ClinicalTrials.gov lists NBI-921352-DEE2013 as Phase 2, primary completion March 2026, last update posted July 17, 2025; no public results/readout are shown in the cited record snippet.
Sponsorscn8aalliance.org
Dear SCN8A Patient Community
Neurocrine says it will discontinue NBI-921352 development for SCN8A-DEE, but the ongoing DEE2013 study will remain open for existing participants. The letter frames this at program level, not as a specific readout for NCT05226780.
Web Searchfdaaa.trialstracker.net
NCT05226780: An ongoing trial by Neurocrine Biosciences
Trial Tracker labels NCT05226780 as ongoing, with results status ongoing and no actual reporting date yet, supporting absence of a completed public readout for this exact trial.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.